Gilead wins a blockbuster consolation prize with EC, Japanese approvals for filgotinib — but that barely softens the blow of the FDA’s CRL

The FDA’s recent slapdown of Gilead’s rheumatoid arthritis JAK filgotinib didn’t even slightly delay its arrival in 2 big world markets. The EC stamped its marketing authorization on the blockbuster candidate at the end of the week, following the news that Japanese regulators had offered its green light a bit…

Click to view original post